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Background  and objective:  The  urgency  of  ebolavirus  drug  development  is  obvious  in light of  the  current
local  epidemic  in  Western  Africa  with  high  morbidity  and  a risk  of wider  spread.  We  present  an  in silico
study  as a ﬁrst  step  to  identify  inhibitors  of ebolavirus  polymerase  activity  based  on approved  antiviral
nucleotide  analogues.
Study design:  Since  a structure  model  of the  ebolavirus  polymerase  is lacking,  we performed  combined
homology  and  ab  initio  modeling  and  report  a similarity  to  known  polymerases  of human  enterovirus,
bovine  diarrhea  virus  and  foot-and-mouth  disease  virus.  This  facilitated  the  localization  of  a  nucleotide
binding  domain  in  the  ebolavirus  polymerase.  We  next  performed  molecular  docking  studies  with
nucleotides  (ATP,  CTP,  GTP  and  UTP)  and nucleotide  analogues,  including  a variety  of  approved  antiviralinding afﬁnity drugs.
Results  and conclusions:  Speciﬁc  combinations  of nucleotide  analogues  signiﬁcantly  reduce  the  ligand-
protein  interaction  energies  of  the  ebolavirus  polymerase  for natural  nucleotides.  Any  nucleotide
analogue  on  its own  did not  reduce  ligand-protein  interaction  energies.  This  prediction  encourages
speciﬁc  drug  testing  efforts  and guides  future  strategies  to inhibit  ebolavirus  replication.
© 2015  Elsevier  B.V.  All  rights  reserved.. Background
Nucleotide analogues are pharmaceuticals for the treatment of a
ariety of viral infections. These drugs inhibit the viral polymerase
y competition for binding of natural (deoxy) ribonucleotide sub-
trates (NTPs) and/or by chain termination upon incorporation into
he nascent viral DNA/RNA chain. Most nucleotide analogues are
dministered as a prodrug that requires intracellular metaboliza-
ion and phosphorylation to promote their interaction with viral
olymerases.
Viral polymerases display signiﬁcant similarities based on com-
on  functions like RNA/DNA template interaction and binding
nd subsequent incorporation of nucleotide building blocks [1,2].
he structure of the ebolavirus polymerase enzyme (Epol) remains
nknown and its sequence of 2212 amino acids (AAs) is too long
∗ Corresponding author at: Laboratory of Experimental Virology, Academic Med-
cal Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
E-mail addresses: f.j.vanhemert@amc.uva.nl (F.J. van Hemert),
.l.zaaijer@amc.uva.nl (H.L. Zaaijer), b.berkhout@amc.uva.nl (B. Berkhout).
ttp://dx.doi.org/10.1016/j.jcv.2015.10.020
386-6532/© 2015 Elsevier B.V. All rights reserved.for a reliable structure prediction by means of combined homol-
ogy and ab initio modeling. Also, sequence similarity of Epol with
polymerases of related viruses is low and the canonical GDD motif
associated with nucleotide binding by viral RNA polymerases is
absent in Epol.
2. Objective
We investigate by means of in silico ligand-protein docking and
interaction energy analysis whether some approved drugs may  also
interact with the RNA-dependent RNA polymerase of ebolavirus,
thus potentially competing with the natural NTPs.
3. Study design
We obtained structure models of subdomains upon tripartition
of the Epol amino acid sequence. A signiﬁcant similarity of the
central domain of Epol was observed with RNA polymerases of
human enterovirus EV71, bovine viral diarrhea virus (BVDV) and
foot-and-mouse disease virus (FMDV), for which detailed structural
information is available [3–5]. Assuming an equivalent function,
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Table 1
Total interaction energy values of ebolavirus polymerase in complex with phospho-
rylated nucleotide analogues.
Interaction (kcal/mol) Epol
Tenofovir-3P −12.51
Favipiravir-3P −11.51
ZidovudineO1-3P −11.47
Ribavirin-3P −11.02
Adefovir-3P −10.45
Abacavir-3P −10.42
Telbivudine-3P −9.68
Entecavir-3P −9.14
Stavudine-3P −8.81
Didanosine-3P −8.53
Emtricitabine-3P −8.37
BCX4430-3P −8.23
Lamivudine-3P −7.26
Sofosbuvir-3P −7.12
F
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e identiﬁed a putative nucleotide binding site in Epol. Next,
e developed an in silico screen that provided the drug struc-
ure in its bioactive conﬁguration. The predicted structure of the
pol nucleotide binding domain, combined with conformational
nformation on the NTPs and nucleotide analogues, facilitated the
odeling of polymerase-ligand complexes (Epol-NTP, Epol-drug
nd Epol-drug-NTP) by means of docking [6]. We  subsequently
etermined the interaction energy proﬁles of these complexes [7].
s a result, combinations of drugs were identiﬁed that reduce the
nteraction energy of Epol for the NTPs to values below those mea-
ured for the nucleotide analogues, thus predicting an impaired
ate of nucleotide incorporation by Epol and a potential therapeutic
ffect.
. Materials and methods
Details of materials and methods are available as Supplementary
ata File S4.
. Results
Ebolavirus RNA polymerase (Epol) showed little similarity with
olymerases of related viruses. In fact, only 20% of the common
mino acids in aligned polymerase sequences of ebolavirus and
V71 or FMDV are identical. Also, the canonical GDD motif asso-
iated with nucleotide binding by polymerases [8] is absent in
pol, but present at a conserved site in EV71, BVDV and FMDV
olymerases. The spatial architecture of Epol may  be more con-
erved than its sequence triggering our attempt to generate a
D-structured model of Epol by means of combined homology and
b initio modeling. The L gene translation product (2210 AAs) of
he ebolavirus genome was divided into three overlapping parts
f 800 AAs each for 3D-modeling by the PHYRE2 server [9]. Most
odeling results of the N- and C-terminal parts were poor due
o the absence of protein templates with established structures,
hich results in low levels of conﬁdence. However, suitable struc-
ure models were obtained for the middle part, in particular for
he central polymerase domain (AAs 680–1065), based on X-ray
tructures of viral RNA polymerases (i.e: EV71, BVDV and FMDV).
his facilitated homology-mediated Epol modeling. The middle
olymerase domain of Epol (AAs 648–1457) displayed signiﬁcant
tructural similarity with the RNA polymerases of poliovirus (PDB
D: 4K4S), human enterovirus EV71 (3N6 M),  rotavirus (2R7X),
epatitis C virus (2YOJ), foot-and-mouth disease virus (2E9R),
hinovirus (4K50) and bovine viral diarrhea virus (1S49). A dendro-
ram of pairwise RMSD distances between these viral polymerases
ubstantiated these relationships (Fig. 1). The structure of EV71
nd BVDV polymerases is available in complex with the GTP
ig. 1. Dendrogram of pairwise distances between polymerases of Ebolavirus and related
istance values and scale bar are in RMSD units representing the average distance (Å) beZidovudineO2-3P −3.89
substrate. The FMDV complex includes a template-primer RNA and
the nucleotide analogue ribavirin. Superposition of these structures
with the predicted Epol structure displayed similar sets of amino
acids in close proximity (within 5 Å) to GTP and ribavirin (Sup-
porting information ﬁles S1 and S2). Based on this observation,
the helical motif 983FLRQIVRR990 (numbers refer to the complete
AA sequence of the Lgene translation product) was selected as an
initial marker for the ribonucleotide binding domain of Epol and
subsequently used to direct the docking procedure [6]. The motif
FLRQIVRR is part of a very well conserved domain in an aligned
selection of diverse Epol representatives (ZEBOV, TAFV, SEBOV,
REBOV, and BEBOV, see Supporting information ﬁle S5).
The most stable position of the four natural nucleotides (NTPs)
is at the “left-hand” side of the FLRQIVRR motif (yellow, Fig. 2),
marking the predicted nucleotide binding domain of Epol. The cor-
responding interaction energy values (ATP: −8.83, CTP: −11.59,
GTP: −9.23 and UTP: −8.96 kcal/mol) are within the range of
experimentally determined and in silico computed values for
ligand-receptor complexes [7], thus supporting the designation of
983FLRQIVRR990 as part of the nucleotide binding domain. Sim-
ilar values were computed for the interaction of Epol with the
individual nucleotide analogues (Table 1). Zidovudine is listed
twice because it offers two alternative sites of phosphorylation
rendering distinct stereoisomeric structures. The isomer with
phosphorylation at O1 showed a high negative value of Epol
binding (−11.49 kcal/mol) in contrast to the O2-phosphorylated
isomer (−3.89 kcal/mol). Stereo-speciﬁc binding of tenofovir to
HBV polymerase has been reported previously [10]. Sofosbu-
vir, zidovudineO2 and lamivudine were excluded from further
 RNA viruses.
tween the C-atoms of the superimposed viral polymerases.
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ucleotides are in green-colored, space-ﬁlled format. The 983FLRQIVRR990 sequence
umbers in brackets are the total interaction energy values (kcal/mol).
nalyses because of their relatively low interaction energy with
pol (−7.12, −3.89 and −7.26 kcal/mol, respectively).
The predicted structure of Epol in complex with the drugs
Fig. 3, two examples are shown) revealed a bipartition among
he nucleotide analogues. The tenofovir group including emtric-
tabine and zidovudine binds at the right-hand side of FLRQIVRR.
he abacavir group including favipiravir, ribavirin, BCX4430, ade-
ovir, didanosine, entecavir, stavudine and telbivudine prefers the
eft-hand side of FLRQIVRR. Binding values (Table 1) vary from
12.51 (tenofovir) to −8.23 kcal/mol (BCX4430). The presence of
ultiple binding sites for NTPs and nucleotide analogues in viral
olymerases is not unprecedented [10,11]. In fact, a three-step
odel of NTP binding, discrimination and incorporation constitutes
 documented route of nucleotide polymerization [12–14].
We  next probed whether the nucleotide drugs could inﬂuenceTP binding to Epol (Table 2). The presence of a drug only inci-
entally reduces the NTP binding value (i.e: Epol-zidovudine-CTP,
4.62 kcal/mol and Epol-didanosine-UTP, −5.39 kcal/mol). We  did
able 2
otal interaction energy values of natural nucleotides with ebolavirus
olymerase—nucleotide analogue complexes. Numbers in bold indicate interaction
nergy values <8.00 kcal/mol.
Interaction (kcal/mol) ATP CTP GTP UTP
Epol −8.83 −11.59 −9.23 −8.96
Epol Tenofovir-3P −11.79 −8.92 −10.58 −8.95
Epol Favipiravir-3P −9.76 −7.32 −10.80 −7.06
Epol ZidovudineO1-3P −9.14 −4.62 −10.41 −8.98
Epol Ribavirin-3P −9.07 −8.16 −11.25 −10.66
Epol Adefovir-3P −9.34 −7.65 −11.04 −9.20
Epol Abacavir-3P −9.90 −9.58 −12.03 −12.65
Epol Telbivudine-3P −10.00 −13.17 −11.25 −7.19
Epol Entecavir-3P −9.40 −12.11 −11.64 −9.20
Epol Stavudine-3P −9.29 −9.63 −11.35 −6.86
Epol Didanosine-3P −9.52 −8.86 −11.64 −5.39
Epol BCX4430-3P −9.52 −9.83 −11.64 −9.58
Epol Emtricitabine-3P −10.27 −7.58 −10.73 −10.87ing the nucleotide binding domain is shown as a yellow-colored ball & stick helix.
not ﬁnd better values by analyzing more complexes outside the
top 20. Only favipiravir is able to affect the binding of more than a
single NTP (CTP and UTP, −7.32 and −7.06 kcal/mol, respectively).
The structures provide more relevant information (Fig. 4, only two
examples shown). The abacavir group binds at the left-hand side,
thus leaving the right-hand side available for ATP, CTP and GTP,
whereas UTP is placed on the left side next to abacavir. The tenofovir
group at the right-hand side allows binding of ATP, CTP, GTP and
UTP at the left-hand side. The other analogues display similar pic-
tures (not shown). Apparently, the presence of a single nucleotide
analogue is not sufﬁcient to inhibit NTP binding. A combination of
drugs may  present a more powerful inhibitory strategy.
In view of the two  NTP binding sites ﬂanking 983FLRQIVRR990
in Epol, combinations of a “left-hand docked” with a “right-hand
docked” drug were tested in silico for the capability to reduce the
NTP interaction. The results are displayed in Table 3. For instance,
the top 1 complex of Epol with ribavirin was  used as a receptor for
tenofovir docking to generate a series of Epol-ribavirin-tenofovir
complexes of which the top 1 model was  selected on the basis of
interaction energy values (PEARLS, [7]). This model was  used as a
Table 3
Total interaction energy values of natural nucleotides in complex with ebolavirus
polymerase carrying two different nucleotide analogues. Numbers in bold indicate
interaction energy values of nucleotides more than 1 kcal/mol lower than those of
the inhibitors.
Interaction energy (kcal/mol)
Docking sequence Inhib(1)* Inhib(2)* ATP CTP GTP UTP
Epol-Riba(1)-Teno(2)-Nuc −11.27 −11.31 −6.23 −5.60 −5.83 −5.83
Epol-Favi(1)-Teno(2)-Nuc −12.28 −10.80 −4.84 −6.83 −7.55 −8.11
Epol-Aba(1)-Teno(2)-Nuc −9.66 −12.07 −7.26 −8.04 −4.22 −11.03
Epol-Telbi(1)-Teno(2)-Nuc −9.79 −11.36 −8.99 −9.32 −6.20 −8.18
Epol-Dida(1)-Teno(2)-Nuc −8.29 −11.62 −8.34 −7.82 −8.25 −6.80
Epol-Aba(1)-Zido(2)-Nuc −9.50 −11.15 −7.52 −8.26 −9.87 −10.34
Epol-Telbi(1)-Emtri(2)-Nuc −9.57 −9.64 −11.44 −10.68 −14.07 −10.95
*  Mean of 4 values: 1 2 3 4
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iig. 3. Different positions of nucleotide analogues after docking into ebolavirus pol
enofovir (example) like emtricitabine and zidovudine are bound at the right-hand s
ntecavir, lamivudine, stavudine and telbivudine prefer the left-hand side of FLRQI
ocking receptor for each of the four NTPs and the resulting models
ere again subjected to PEARLS analysis to identify the top 1 model.
ence, the interaction energy values of the inhibitors (marked by
sterisks) represent the average of the four (top 1) analyses. A low
or highly negative) value for interaction energy reﬂects a high
fﬁnity of the partners in the complex. The interaction energy val-
es of the inhibitors (−11.27 and −11.31 kcal/mol for ribavirin and
enofovir, respectively) are considerably lower than the values for
TP, CTP, GTP and UTP (−6.23, −5.60, −5.83 and −5.83 kcal/mol,
espectively) in the same complex.
Based on these observations, the combined administration of
peciﬁc drug combinations may  strongly inhibit the in vivo binding
nd polymerization of ATP, CTP, GTP and UTP by Epol (Table 3 and
upporting information ﬁle S3). For instance, the Epol-favipiravir-
enofovir complex has a profound effect on the interaction with
ach of the four NTPs (ATP: −4.84, CTP: −6.83, GTP: −7.55 and UTP:
8.11 versus favipiravir: −12.28 and tenofovir: −10.80 kcal/mol).
avipiravir has been reported to exhibit antiviral activity against
bolavirus [15]. The combination of abacavir with tenofovir affects
he binding energy of three of the four NTPs (ATP: −7.26, CTP: 08.04,
TP: −4.22 and UTP: −11.03 versus abacavir: −9.66 and teno-
ovir: −12.07 kcal/mol). Telbuvidine plus tenofovir scored −8.99
ATP), −9.32 (CTP), −6.20 (GTP) and −8.18 (UTP) versus −9.79
telbivudine) and −11.36 (tenofovir) kcal/mol. Other combinations
ig. 4. Binding sites of the natural nucleotides in the presence of a single nucleotide anal
enofovir and abacavir represent examples of nucleotide analogues docking at the right-h
and  side” or “left-hand side” bound nucleotide analogue, the natural nucleotides are bou
n  green and nucleotide analogues in red space-ﬁlled format.se.
FLRQIVRR. Abacavir (example), ribavirin, favipiravir, BCX4430, adefovir, didanosine,
ellow-colored helix). Nucleotide analogues are in red-colored, space-ﬁlled format.
(didanosine plus tenofovir, abacavir plus zidovudine and telbivu-
dine plus emtricitabine) scored signiﬁcantly less with respect
to the interaction energy parameters (Table 3). The correlation
coefﬁcient between experimental and computed energy values is
0.79 kcal/mol [7]. The standard error for computed free energy is
0.45 kcal/mol [7]. It should be noted that the measure of interaction
energy values is logarithmically related to the equilibrium constant
of the enzyme-substrate reaction involved. Consequently, a differ-
ence of 1 kcal/mol indicates a 10-fold difference of afﬁnity in the
most simple E + S⇔ES model.
Thus far, we  analyzed the top 1 models of the Epol-drug-
NTP complexes that have the most negative values for interaction
energy. It may  be considered that a nucleotide analogue occupies
both the left-hand and right-hand sites of Epol and that, in these
cases, mixed drug complexes like Epol-AB or Epol-BA may perform
less in the competition with NTPs than Epol-AA or Epol-BB com-
plexes. Interaction energy values of the top 1 models generally
show signiﬁcantly better afﬁnity values (>1 kcal/mol) than those
of the (second best) top 2 models. For instance, the top 1 en top 2
models of Epol with ribavirin both prefer the left-hand site of the
binding region, notably with very different afﬁnities (−11.02 and
−6.54 kcal/mol, respectively). Similarly, abacavir (top 1; −10.42
and top2: −7.75) and favipiravir (−11.51 and −10.06 kcal/mol)
docked at the left-hand site like the three top models of
ogue.
and site and left-hand site of FLRQIVRR, respectively. In presence of either a “right-
nd at the opposite side of FLRQIVRR (yellow-colored helix). Natural nucleotides are
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elbivudine (−9.68, −9.14 and −8.26 kcal/mol). The two top mod-
ls of Epol with the nucleotide analogue tenofovir displayed
n opposite site preference, but with different afﬁnities (top
; −12.51 kcal/mol, right-hand site and top 2; −11.28 kcal/mol,
eft-hand site). When two drugs with opposite site preference
re employed, the formation of mixed drug Epol-AB or Epol-BA
omplexes is energetically more likely than Epol-AA or Epol-BB
omplexes.
. Discussion
The Epol model presented above has been generated in silico by
eans of combined homology and ab initio modeling of the central
pol domain. In general, modeling of Epol sequences showed poor
uality due to the absence of similar protein structures that should
rovide the templates for the homology-mediated part of the mod-
ling process. For the central domain of Epol, viral polymerase
tructures were available as templates for homology modeling and,
ence, Epol modeling rendered a local structure common to a vari-
ty of remotely related polymerases, allowing the identiﬁcation of
 putative NTP binding region by means of structure/function sim-
larity. An important caveat is the absence of an RNA template with
nnealed primer in the Epol model. Localization of an RNA bind-
ng domain via an alternative, but similar strategy (superposition
f Epol with RNA carrying polymerases) failed due to the lack of a
ommon core of Epol residues in the superpositions. Different poly-
erases may  carry different RNA templates and the RNA-binding
omain may  also—partially or completely—be positioned outside
he middle portion of the Epol sequence. We  provided the Epol
tructure with “left-hand” and “right-hand” docked drugs relative
o the FLRQIVRR marker of the NTP binding site and determined
he capacity of these complexes to bind NTPs. This survey indicates
hat the NTPs are prevented to occupy their regular position due
o the presence of two nucleotide analogues at distinct sites of the
inding region (Supporting information ﬁle S3).
This study addressed the competition of nucleotide analogues
ith NTP binding in the Epol enzyme. Besides this competition,
any drugs interfere with virus replication by chain termination
nd/or lethal mutagenesis as a relevant inhibitory mechanisms.
or instance, the dGTP analogue abacavir has a ribose without the
′-OH group that is essential for chain elongation [16]. Telbivu-
ine is an unmodiﬁed -L-enantiomer of TTP [17]. Incorporation
f telbivudine-5′-triphosphate into viral DNA causes DNA chain
ermination, resulting in inhibition of virus replication. The actual
ntiviral mechanism for the ribonucleotide analogue ribavirin is
oorly understood. In short, ribavirin may  also cause lethal mutage-
esis upon incorporation in the viral genome. In addition, ribavirin
s a potent inhibitor of mRNA-guanylyltransferase responsible for
apping of mRNA, and of IMP  dehydrogenase, thus reducing the
evel of host cellular GTP that acts as energy source during protein
ynthesis [18]. The prodrug favipiravir, intracellularly metabolized
nto favipiravir-ribofuranosyl-triphosphate, acts as pseudo purine
nd also causes lethal mutagenesis upon incorporation [19]. The
urine analogue tenofovir, which is intracellularly triphosphory-
ated, displays high afﬁnity values for HIV, HBV and ebolavirus
olymerases, although the ribose moiety is absent in its bioac-
ive structure [20]. Many databases and similar resources report
ncorporation of tenofovir in the growing nucleotide chain, which
bviously leads to chain termination. Viral polymerases may  be
apable to discern between ribonucleotides and deoxyribonu-
leotides during RNA/DNA chain elongation [2,21,22], which in case
f tenofovir is impossible due to the absence of a (deoxy) ribose.
he capability of ribose/deoxyribose discrimination by Epol and
he mechanism of tenofovir incorporation in viral genomes deserve
uture attention.
[ical Virology 73 (2015) 89–94 93
In conclusion, the administration of speciﬁc combinations of
nucleotide analogues, such as ribavirin plus tenofovir, favipiravir
plus tenofovir, abacavir plus tenofovir, or telbivudine plus teno-
fovir, may  impair ebolavirus polymerase activity and limit virus
replication and consequently its pathogenic effects. A concerted
drug action may  offer an additional antiviral impact because the
evolution of drug-resistant virus variants will be delayed or even
prevented. The clinical need for anti-Ebola agents is pressing in
Western Africa and even a partial reduction of virus replication
may  allow the infected individual to mount a protective immune
response, which could be boosted by an antibody-based treatment
[23] to trigger clearance of this pathogen.
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